(CercleFinance.com) – Biosynex announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical, by signing an exclusive agreement for the distribution of VitaPCR systems for an extended territory including the United Kingdom.
In addition, according to the new agreement, Credo Diagnostics will launch a next-generation rapid PCR platform, VitaSIRO solo, based on microfluidics that simplifies the entire procedure.
At the start of the Covid-19 health crisis in March 2020, the French rapid diagnostic test company and Credo Diagnostics had agreed on a distribution agreement for VitaPCR systems for France, Belgium, Switzerland and Luxembourg.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
